<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01705938</url>
  </required_header>
  <id_info>
    <org_study_id>SP333101</org_study_id>
    <nct_id>NCT01705938</nct_id>
  </id_info>
  <brief_title>Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of SP-333 Tablets in Healthy Adult Subjects</brief_title>
  <official_title>A First In Human, Single Blind, Placebo Controlled, Randomized Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SP-333 Tablets in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch Health Americas, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch Health Americas, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, phase 1, single-blind, placebo-controlled, randomized, sequential,&#xD;
      escalating, single-dose, study designed to evaluate the safety, tolerability,&#xD;
      pharmacodynamics (PD) and pharmacokinetics (PK) properties of orally administered SP-333&#xD;
      tablets.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, phase 1, single-blind, placebo controlled, single-dose, study designed&#xD;
      to evaluate the safety, tolerability, and pharmacokinetic properties of orally administered&#xD;
      SP-333 tablets. The study will include 7 groups of 8 subjects each (6 active, 2 placebo)&#xD;
      given a single oral dose of of SP-333 tablets or placebo. Following outpatient screening from&#xD;
      approximately 5 to 42 days before dosing, each subject will enter the Clinical Pharmacology&#xD;
      Unit (CPU) and will be housed from at least 48 hours, before dosing until 48 hours after&#xD;
      dosing. Subjects will be given single dose of the study drug on the day of dosing and remain&#xD;
      in the CPU for at least 48 hours. Subjects will return to the CPU on Days 8±1 and 15±1 for&#xD;
      safety follow up. Safety Committee Meetings will be conducted to review safety, tolerability,&#xD;
      and available Pharmacokinetic data from the current and previous treatment group(s), prior to&#xD;
      dosing subsequent treatment groups. Subjects in a given treatment group are considered&#xD;
      completers once they have completed the Day 15±1 day Follow up Visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with treatment emergent adverse events as a measure of safety and tolerability</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of SP-333 following single oral doses of tablets.</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Exposure</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SP-333 0.1 mg &amp; Placebo, one tablet by mouth, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SP-333 0.3 mg &amp; Placebo, 3 tablets by mouth, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SP-333 1 mg &amp; Placebo, one tablet by mouth, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SP-333 3 mg &amp; Placebo, 3 tablets by mouth,single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SP-333 10 mg &amp; Placebo, 1 tablet by mouth, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SP-333 30 mg &amp; Placebo, 3 tablets by mouth, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 7</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SP-333 60 mg &amp; Placebo, 6 tablets by mouth, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SP-333</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_label>Group 7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects between 18 and 55 years old&#xD;
&#xD;
          2. Body weight greater than or equal to 50 kg (110 pounds) and Body Mass Index (BMI) in&#xD;
             the range of 18 to 30 kg/ m2&#xD;
&#xD;
          3. Medically healthy with no clinically significant findings.&#xD;
&#xD;
          4. Subjects must have bowel habits that are considered regular (for this study a minimum&#xD;
             of 4 bowel movements a week without laxatives).&#xD;
&#xD;
          5. Subject must have had a bowel movement, without laxatives, in the 3 days before&#xD;
             administration of study drug.&#xD;
&#xD;
          6. Male subjects with female sexual partners of child-bearing potential must agree to use&#xD;
             highly effective contraceptive methods during the study.&#xD;
&#xD;
          7. Female subjects must be post-menopausal and not pregnant.&#xD;
&#xD;
          8. Subjects must understand and agree to comply with the requirements of the study and&#xD;
             they must be willing to sign an Informed Consent Form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Smokers or users of nicotine products who do not agree to not smoke or use nicotine&#xD;
             products during their stay in the CPU.&#xD;
&#xD;
          2. Current or history of clinically significant diseases, including gastrointestinal,&#xD;
             renal, hepatic, neurologic (e.g., neuropathy), hematologic, endocrine (e.g.,&#xD;
             diabetes), oncologic, pulmonary, immunologic, psychiatric, or cardiovascular disease&#xD;
             or any other condition.&#xD;
&#xD;
          3. Presence of any abnormal clinically significant laboratory.&#xD;
&#xD;
          4. History of any serious allergic reaction to any medication&#xD;
&#xD;
          5. Certain abnormalities of the ECG.&#xD;
&#xD;
          6. Participated in a previous clinical study with an investigational product within 30&#xD;
             days of study Participation&#xD;
&#xD;
          7. Donated blood, blood components or significant loss of blood within 2 months of dosing&#xD;
&#xD;
          8. History of a clinically-significant illness within 4 weeks of dosing&#xD;
&#xD;
          9. Special diet, any dietary habits, or restrictions, which, may interfere with conduct&#xD;
             of the study or health of the subject within 30 days of dosing&#xD;
&#xD;
         10. History of clinically-significant drug or alcohol abuse within 2 years of study&#xD;
             participation&#xD;
&#xD;
         11. Positive urine screen for prohibited drugs (cocaine, cannabinoids, opiates,&#xD;
             barbiturates, amphetamines, benzodiazepines, phencyclidine, propoxyphene).&#xD;
&#xD;
         12. History of human immunodeficiency virus (HIV), hepatitis B surface antigen positive&#xD;
             (+HBsAg), or hepatitis C antibody positive (+HCVAb).&#xD;
&#xD;
         13. History of certain surgeries:&#xD;
&#xD;
               -  Gastric bypass surgery or invasive procedure for the treatment of obesity or&#xD;
                  surgery to remove a segment of the gastrointestinal (GI) tract at any time.&#xD;
&#xD;
               -  Patients who have had a gastric band (unless the band has been completely removed&#xD;
                  for more than 60 days)&#xD;
&#xD;
               -  Surgery of the abdomen, pelvis or retroperitoneal structures within six months of&#xD;
                  study participation.&#xD;
&#xD;
               -  Appendectomy,Instrumentation of the bowel, major surgery within 60 days of study&#xD;
                  participation.&#xD;
&#xD;
         14. Female subjects of childbearing potential or who are breastfeeding&#xD;
&#xD;
         15. Use of any routine systemic medication, including any over the counter (OTC)&#xD;
             medication within 2 weeks of dosing&#xD;
&#xD;
         16. Use of herbal products, dietary supplements, vitamins, grapefruit, or grapefruit&#xD;
             containing products within 2 weeks of dosing&#xD;
&#xD;
         17. Irregular daily bowel habits&#xD;
&#xD;
         18. Any other issue which, in the judgment of the investigator, will make the subject&#xD;
             ineligible for study participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Winkle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anaheim Clinical Trials</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anaheim Clinical Trials</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>October 8, 2012</study_first_submitted>
  <study_first_submitted_qc>October 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2012</study_first_posted>
  <last_update_submitted>May 23, 2019</last_update_submitted>
  <last_update_submitted_qc>May 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dolcanatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

